P005 Multimarker approach to assessment of cardiac toxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia

Horáček, Jan M.; Tichý, M.; Jebavý, Ladislav; Pudil, Radek; P, Žák; Blaha, V.; Slováček, Ladislav; Palička, Vladimír

doi:10.1016/s0268-960x(07)70078-4

Cited by 19 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently published studies reported significant BNP/ NT-proBNP elevations after HD-CT and hematopoietic cell transplantation [57][58][59][60] . Persistent BNP/NT-proBNP elevations early after HD-CT were observed in 33 -47% patients and were associated with the development of cardiac dysfunction during the follow-up.…”

Section: Natriuretic Peptides As Markers Of Ct-induced Cardiotoxicitymentioning

confidence: 99%

“…Since 2007, we have published several papers dealing with multiple biomarkers of cardiac injury, including GPBB and H-FABP, to detect cardiotoxicity associated with CT for hematological malignancies -conventional CT containing anthracyclines and HD-CT followed by hematopoietic cell transplantation [73][74][75][76][77][78] . In our study on 24 acute leukemia patients treated with anthracycline-based CT (mean age 48.1 ± 10.9 years, 13 males, mean total cumulative anthracycline dose 463.2 ± 114.3 mg/m 2 ), we found significant elevations in GPBB after CT containing anthracyclines (in 16.7% and 20.8% patients, respectively).…”

Section: Perspective Markers Of Ct-induced Cardiotoxicity (Under Study)mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. Cardiotoxicity is a well-known and potentially serious complication of anticancer therapy. Anthracyclinebased chemotherapy represents the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. Methods and Results. Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome. Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. Increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have provided encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined. Conclusions. This review covers the current status of biomarkers for the early detection of anthracycline-induced cardiotoxicity. The authors present in brief, their own experience with multiple biomarkers in the detection of cardiotoxicity.

show abstract

Section: Natriuretic Peptides As Markers Of Ct-induced Cardiotoxicitymentioning

confidence: 99%

Section: Perspective Markers Of Ct-induced Cardiotoxicity (Under Study)mentioning

confidence: 99%

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Horáček¹,

Vašatová²,

Pudil³

et al. 2014

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

show abstract

“…С конца 90-х годов XX столетия предпринима-лись попытки использовать NT-proBNP и BNP для оцен-ки кардиотоксичности при лечении ОЗ [53,54]. Выявлено повышение уровня этих пептидов у пациентов, получав-ших терапию антрациклинами в кумулятивной дозе более 450 мг/м 2 [55] и циклофосфамидом в режиме кондицио-нирования [56], а также после аутологичной транспланта-ции костного мозга (ТКМ). Повышенный уровень пепти-дов может сохраняться после окончания лечения в тече-ние длительного периода времени -факт, неблагоприят-ный для прогноза.…”

Section: ие чазова и соавтunclassified

“…Повышенный уровень пепти-дов может сохраняться после окончания лечения в тече-ние длительного периода времени -факт, неблагоприят-ный для прогноза. Ряд авторов считают, что BNP и NTproBNP являются более чувствительными показателями развития кардиотоксичности, чем уровень тропонина и данные ЭхоКГ [55,57]. Следует иметь в виду и другие воз-можные причины повышения уровня BNP, например по-чечную недостаточность [56].…”

Section: ие чазова и соавтunclassified

Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy

Чазова¹,

Ev²,

Ay³

2015

Ter. arkh.

View full text Add to dashboard Cite

Section: • 25 Perspective Markers Of Ct-induced Cardiotoxicity (Undmentioning

confidence: 99%

Biomarkers of Cardiac Injury in Detection of Cardiotoxicity Induced by Chemotherapeutic Agents

Horáček¹

2011

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

SummaryCardiotoxicity is a well-known and potentially serious complication of oncology treatment. Anthracyclines and high-dose chemotherapy especially regimens containing high-dose Cyclophosphamide represent the greatest risk. Early detection of cardiotoxicity is crucial for applying preventive and supportive therapeutic strategies. Various methods have been recommended for monitoring of cardiotoxicity. In our conditions, echocardiography and electrocardiography are routinely used. However, this approach shows low sensitivity for the early prediction of cardiomyopathy when the possibilities of appropriate management could still improve the patient's outcome.Recently, biomarkers of cardiac injury have been investigated in the assessment of chemotherapy-induced cardiotoxicity. Cardiospecific biomarkers, such as cardiac troponins, show high diagnostic efficacy in the early subclinical phase of the disease before the clinical onset of cardiomyopathy. The increase in their concentrations correlates with disease severity. As for natriuretic peptides, some studies, including ours, have shown promising results. Definitive evidence of their diagnostic and prognostic role in this context is still lacking and natriuretic peptides have not been routinely used for monitoring of cardiotoxicity in clinical practice. Other perspective biomarkers of cardiotoxicity in oncology are under study, especially heart-type fatty acid-binding protein (H-FABP) and glycogen phosphorylase BB (GPBB). Our studies using GPBB have brought priority and encouraging results. However, the available data are limited and their practical use in this context cannot be recommended until their clinical efficacy is clearly defined.The author presents his own experience with multiple biomarkers of cardiac injury in the detection of cardiotoxicity associated with conventional and high-dose chemotherapy for hematological malignancies.

show abstract

P005 Multimarker approach to assessment of cardiac toxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia

Cited by 19 publications

References 0 publications

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status

Comorbidity of cardiovascular diseases and cancers: Problems in the diagnosis of cardiotoxic effects of chemo- and radiation therapy

Biomarkers of Cardiac Injury in Detection of Cardiotoxicity Induced by Chemotherapeutic Agents

Contact Info

Product

Resources

About